Absorption of tobramycin from the gut in critically ill patients treated with selective decontamination of the digestive tract (SDD)

• Conditions: 10002252; antibiotics; permeability

• Registration Number: NL-OMON30143
• Lead Sponsor: Onze Lieve Vrouwe Gasthuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Critically ill patients acutely admitted to the intensive care patients, treated with selective decontamination of the digestive tract for at least 24 hours.

Exclusion Criteria

Intravenous use of tobramycin or gentamycin

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>concentrations of tobramycin in blood<br /><br>excretion of tobramycin in urine</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>renal function<br /><br>SOFA score<br /><br>APACHE score</p><br>